CD28 blockade alters cytokine mRNA profiles in cardiac transplantation

Surgery

Volumn 122, Issue 2, 1997, Pages 129-137

  Lin, Hua ^b   Wei, Ru Qi ^b   Goodman, Richard E ^b   Bolling, Steven F ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOKINE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

EID: 0030772479     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(97)90001-5     Document Type: Conference Paper

References (25)

1. Marrack P, Kappler J. The T cell receptor. Science 1987;238:1073-9.
2. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-56.
3. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173:721-30.
4. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9.
5. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990;87:5031-6.
6. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei RQ, et al. T cell activation by the CD28-ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89:11102-5.
7. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, et al. Long-term tolerance to major histocompatibility complex mismatched cardiac allografts induced by CTL2AY4Ig plus donor specific transfusion. J Med Exp 1993;178:1801-6.
8. Harding FA, McArthur JG, Gross JA, et al. CD28-mediated signalling costimulates murine T cells and prevents induction of anergy in T cell clones. Nature 1992;356:607-11.
9. Thompson CB, June CH, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell derived lymphokines/cytokines. Proc Natl Sci USA 1989;86:1333-7.
10. Perico N, Imberti O, Bontempelli M, Remuzzi G. Toward novel antirejection strategies: in vivo immunosuppresive properties of CTLA4Ig. Kidney Int 1995;47:241-6.
11. Matsumura Y, Zuo XJ, Prehn J, et al. Soluble CTL A4Ig modifies acute rejection of rat lung allografts without blocking accumulation of key cytokine transcripts. Transplant Proc 1995;27:406-8.
12. Matsumura Y, Zuo XJ, Prehn J, et al. Soluble CTLA4Ig modifies parameters of acute inflammation in rat lung allograft rejection without altering lymphocytic infiltration or transcription of key cytokines. Transplantation 1995;27:551-8.
13. Pescovitz MD, Yeng R, Liu Q, Collins MH, Grosfeld JL. CD28-pathway blockade with CTLA4Ig leads to prolongation of small bowel transplant survival in rats. Transplant Proc 1994;26:1618-9.
14. Baliga P, Chavin KD, Qin L, et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994;58:1082-90.
15. Tepper MA, Linsley PS, Tritschler D, Esselstyn JM. Tolerance induction by soluble CTLA4 in a mouse skin transplant model. Transplant Proc 1994;26:3151-4.
16. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4Ig. Transplantation 1994;57:1701-6.
17. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-92.
18. Bolling SF, Lin H, Wei RQ, Linsley P, Turka LA. The effect of combination cyclosporine and CTLA4Ig therapy on cardiac allograft survival. J Surg Res 1994;57:60-4.
19. Dallman MJ, Shiho O, Page TH, Wood KJ, Morris PJ. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991;173:79-87.
20. McKnight AJ, Mason DW, Barclay AN. Sequence of rat interleukin2 and anomalous binding of a mouse interleukin2 cDNA probe to rat MHC class II-associated invariant chain mRNA. Immunogenetics 1989;30:145-7.
21. Zembala M, Siedlar M, Ruggiero I, Wieckiewicz J, Mytar B, Mattei M, et al. The MHC class-II and CD44 molecules are involved in the induction of tumour necrosis factor (TNF) gene expression by human monocytes stimulated with tumour cells. Int J Cancer 1994;56:269-74.
22. Panek RB, Benveniste EN. Class II MHC gene expression in microglia: regulation by the cytokines IFN-gamma, TNF-alpha, and TGF-beta. J Immunol 1995;154:2846-54.
23. Burstein HJ, Abbas AK. In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen. J Exp Med 1993;177:457-63.
24. Rivas JM, Ullrich SE. The role of IL-4, IL-10, and TNF-alpha in the immune suppression induced by ultraviolet radiation. J Leukoc Biol 1994;56:769-75.
25. Abramowicz D, Durez P, Gerard C, et al. Neonatal induction of transplantation tolerance in mice is associated with in vivo expression of IL-4 and -10 mRNAs. Transplant Proc 1993;25(pt 1):312-3.